The invention is directed to a method of inhibiting bone resorption. The methodcomprises administering to a human an amount of sclerostin inhibitor that reducesa bone resorption marker level for at least 2 weeks. The invention also providesa method of monitoring anti-sclerostin therapy comprising measuring one ormore bone resorption marker levels, administering a sclerostin binding agent,then measuring the bone resorption marker levels. Also provided is a method ofincreasing bone mineral density； a method of ameliorating the effects of an osteoclast-relateddisorder； a method of treating a bone-related disorder by maintaining bone density；and a method of treating a bone-related disorder in a human suffering from or atrisk of hypocalcemia or hypercalcemia, a human in which treatment with a parathyroidhormone or analog thereof is contraindicated, or a human in which treatment witha bisphosphonate is contraindicated.
